Breakthrough discovery paves the way for new methods to detect and treat leukemia

Pfiz­er’s new cer­vi­cal can­cer drug Tiv­dak has been con­vert­ed from an ac­cel­er­at­ed to a full ap­proval. The Seagen and Gen­mab-parterned drug, al­so known as ti­so­tum­ab ve­dotin-tftv,

For patients with attention-deficit/hyperactivity disorder (ADHD), starting medication was associated with a significantly lower risk of death, particularly from “unnatural” causes, according to an observational